• DOV Pharmaceutical Inc., of Somerset, N.J., entered a restructuring support agreement with an ad hoc committee of its 2.5 percent convertible subordinated note holders. Those with 88 percent of the debt have agreed to DOV's offer to exchange the $70 million of notes for one or more new series of convertible preferred stock and an aggregate $14.9 million cash payment, and not take any actions or exercise any remedies relating to DOV's Jan. 3 failure to repurchase the debt pursuant to an offer to repurchase, unless the company enters bankruptcy proceedings or they are commenced against DOV. The company will offer all debt holders eight shares of a new series of convertible preferred stock, par value $1 apiece with a liquidation preference of $100 each, plus a cash payment of $212.50, for each $1,000 of debt they hold. DOV currently has about 26.7 million common shares outstanding, and if all the notes are tendered, the bondholders would hold about 107 million shares or 80 percent of its equity, without giving effect to any warrants and existing and future equity incentive plans.

• ExonHit Therapeutics SA, of Paris, received €3.2 million (US$4.1 million) through the exercise of warrants leading to the issuance of 409,815 new shares. The company said that funding, along with the €15.3 million brought in through the issuance of convertible bonds in November, strengthens its cash position. ExonHit markets microarrays designed to analyze RNA splicing and it is developing a therapeutic pipeline in neurodegenerative disease and cancer.

• ImClone Systems Inc., of New York, said Erbitux's full-year global sales totaled $1.1 billion for the period ended Dec. 31. Its U.S. in-market sales reached $652.2 million in the same period, $167.2 million of which came in the preceding three months. The company realized total quarterly revenues of $132.2 million, generating 53 cents in diluted earnings per share for the quarter.

• Integrated BioPharma Inc., of Hillside, N.J., received approval to list its common shares on the Nasdaq Global Market as "INBP." It will begin trading on that exchange after some final regulatory requirements are completed, which the company expects to occur on Feb. 5, at which time the stock will be de-listed from the American Stock Exchange.

• Inyx Inc., of New York, said its plans to go private are nearly complete. A buyout group is completing its valuation over the next three to four weeks and plans to present a cash offer next month. In addition, the specialty pharmaceutical company said financing has been arranged for its pending acquisition of the pharmaceutical packaging firm Pharmapac UK Ltd., of Bidston, UK.

• Lentigen Corp., of Baltimore, and Wave Biotech LLC, of Somerset, N.J., entered a collaboration in which Wave Biotech will provide process and equipment expertise for Lentigen's manufacturing platform based on its lentiviral vector technology. Financial terms of the agreement were not disclosed.

• Resverlogix Corp., of Calgary, Alberta, retained UBS Securities to act as the financial advisor to assist in evaluating the company's strategic alternatives, which are focused on securing an agreement regarding its NexVas Plaque Regression (NexVas PR) technologies. Resverlogix said its goal is to partner or sell the technology to a pharmaceutical firm that can advance it through clinical trials and into the market. NexVas PR targets ApoA-1 enhancement via small molecules for plaque stabilization and regression.

• UCB SA, of Brussels, Belgium, said the Committee for Medicinal Products for Human Use recommended that European regulators grant a marketing application for Xyrem (sodium oxybate) in narcolepsy with cataplexy in adult patients. The European Commission is expected to issue a decision within about six weeks. Xyrem was designated an orphan drug in 2003.